Brief: Reviva Pharmaceuticals Announces Letter To Shareholders
04/01/2023 11:02
Jan 4 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
RVPH.O :
* REVIVA PHARMACEUTICALS ANNOUNCES LETTER TO SHAREHOLDERS
* REVIVA PHARMA - ON TRACK TO REPORT TOP-LINE DATA IN
MID-2023
FROM GLOBAL, PIVOTAL PHASE 3 RECOVER TRIAL OF BRILAROXAZINE IN
SCHIZOPHRENIA PATIENTS
Source text for Eikon: ID:nGNX41jVcP
Further company coverage: RVPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reviva Pharmaceuticals Holdings
See all newsReviva Pharmaceuticals Q1 net loss narrows on lower expenses
Brief: Reviva Pharmaceuticals Holdings Inc - To Be Delisted From Nasdaq Trading Suspended As Of May 14, 2026 - SEC Filing
Brief: Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture